The U.S. FDA has approved
Farxiga (dapaglifozin) tablets for
adults with type 2 diabetes.
Dapaglifozin propanediol
monohydrate was approved in
Australia under specific conditions
on 05 Oct 2012 and sponsored by
Bristol-Myers Squibb.
Farxiga had been rejected in the
US previously over safety concerns
but an outside advisory panel said
the benefits outweighed the risks,
Reuters reported.
The Australian submission details
can be viewed by CLICKING HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 14
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.